Renal diagnostics company RenalSense has received $14m in a Series A funding round to commercialise its critical care monitoring system Clarity RMS.

Led by BlueRed Partners Fund, the funding round saw participation from several healthcare-focused investors.

BlueRed Partners is a Singapore-based fund focused on investing in disruptive, and early growth-stage Israeli technology companies.

RenalSense also plans to expand the clinical validation of Clarity RMS to additional clinical settings, and advance the next-generation products based on its sensor platform.

BlueRed Partners managing partner and co-founder Yishai Klein said: “RenalSense is a front-runner in digitalizing real-time renal monitoring, providing intensivists with a key indicator of vital organ function they have not had access to before.

“With increasing adoption by leading medical centers in the US and Europe, we look forward to supporting the company’s growth as it extends its reach to Asia and expands its product line.”

Clarity RMS is a critical care monitoring system that facilitates early detection of changes in renal function and Acute Kidney Injury (AKI) risk, along with treatment monitoring.

It is the company’s first commercially available product, and has received the US Food and Drug Administration (FDA) and CE mark approvals.

Clarity RMS has been installed in various general and cardiovascular operating rooms and intensive care units (ICU’s) in the US, Europe and Israel, said the company.

RenalSense aims to create sensor-based products in future that provide additional diagnostic data about renal and other vital organ function, beyond the critical care setting.

Its existing distribution partners include Fresenius Medical Care (Europe), Medline (North America), and Gloryway (China).

The company has also expanded its global marketing network with new distributors in eastern Europe and Israel last year, and most recently with PAHSCO, in Taiwan.

RenalSense CEO Avi Kleiman said: “With the recent publication of clinical data demonstrating the clinical value of the Clarity RMS in the ICU setting, we are forging ahead with validation in additional areas like cardiology and anaesthesia, in parallel with developing our pipeline of sensor-based products.

“We are excited to have new investors on board who share our vision and understand the importance of digitally monitoring real-time renal function, bringing this parameter on par with the other vital signs of hospitalized patients.”